Market Cap 4.08M
Revenue (ttm) 0.00
Net Income (ttm) -20.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 21,800
Avg Vol 37,474
Day's Range N/A - N/A
Shares Out 2.24M
Stochastic %K 30%
Beta 0.97
Analysts Strong Sell
Price Target $10.00

Company Profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly kno...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 427 2727
Address:
Three Columbus Circle, 15th Floor, New York, United States
TwongStocks
TwongStocks Apr. 1 at 12:43 PM
$INDP Decoy20 didn't make it past Phase 1, another Meckler dud (anyone else remember Accordion Pill?). Seems to me that with the management changes, they plan to pivot to something else. Most likely a shift away from biotech, due to the lack of biotech/medical experience of the new investors. Low OS, only 2.24m shares. If the new investors can secure some funding when they announce their strategic pivot, ideally via a PIPE with multiple institutional investors, that could bring increased interest and volume here. Decent chance for a quick spike from these levels, if they can execute.
1 · Reply
TruthTooPower
TruthTooPower Mar. 31 at 7:54 PM
$INDP!!! Keep it Up!!! Just Before Open Telegraphing Where this is Headed!! !!!!!!!!!!!!!$2.75!!!!!!!!!!!!!!
0 · Reply
BadBankofGotham
BadBankofGotham Mar. 31 at 11:58 AM
0 · Reply
MikiTrader
MikiTrader Mar. 28 at 5:36 PM
$INDP After taking massive losses, it looks like they can’t play games anymore.😂
0 · Reply
TwongStocks
TwongStocks Mar. 25 at 2:15 AM
$INDP The new CEO and Chairman does not have a scientific or biotech background. Meckler and Dr. Pomerantz are out. Really looks like INDP is going to go through a complete transformation. Not sure what they'll end up doing, but I don't think this will be a biotech company anymore.
1 · Reply
TwongStocks
TwongStocks Mar. 24 at 8:42 PM
$INDP And here is the 8-k that identifies all the investors that bought Lazar's preferred shares: https://www.sec.gov/ix?doc=/Archives/edgar/data/1857044/000149315226012372/form8-k.htm Also, there will be massive changes at INDP. Meckler, Pomerantz, Maddaluna, & Hayes are resigning from the Board. Meckler is also resigning as co-CEO. Lazar resigns as co-CEO & Chairman, but remains on the Board. Junyi Dai is now Chairman & CEO.
1 · Reply
TwongStocks
TwongStocks Mar. 24 at 8:19 PM
$INDP New 13D filing from David Lazar. He sold most of his preferred shares. As a result, his beneficial ownership drops to 2,064,000 shares, 47.93%. He also resigned as co-CEO, but he retains his seat on the Board of Directors. https://www.sec.gov/Archives/edgar/data/1857044/000182912626002642/xslSCHEDULE_13D_X02/primary_doc.xml Under Item 6 at the bottom of the filing: He sold to Yun Yao (lead investor) and other purchasers: • 700,000 shares of Series AAA Preferred Stock (convertible to 105m shares) • 196,800 shares of Series AA Preferred Stock (convertible into 3.936m shares) • Lazar retains 103,200 shares of Series AA Preferred Stock (convertible into 2.064m shares). • Total sale price $11.2M. Lazar originally purchased all his preferred shares in Dec for $6M. So he got $11.2M and still kept 103.2k Series AA preferred shares. Pretty good swing for him. I guess his work here is done, he is no longer co-CEO. Picked up preferred shares, flipped them, and split.
0 · Reply
TruthTooPower
TruthTooPower Mar. 23 at 1:07 PM
$GRI!!! $INDP !!! $IRD !!! Get Ready To Rumble!!!
0 · Reply
TruthTooPower
TruthTooPower Mar. 20 at 12:04 PM
$INDP!!! 🤓
0 · Reply
TruthTooPower
TruthTooPower Mar. 20 at 11:56 AM
$INDP!!! This Traded At $2.74 at 4 am this Morning!!!
0 · Reply
Latest News on INDP
Indaptus Therapeutics Provides Clinical Update

Sep 4, 2025, 4:01 PM EDT - 7 months ago

Indaptus Therapeutics Provides Clinical Update


Indaptus Therapeutics Announces Reverse Stock Split

Jun 25, 2025, 7:00 AM EDT - 10 months ago

Indaptus Therapeutics Announces Reverse Stock Split


TwongStocks
TwongStocks Apr. 1 at 12:43 PM
$INDP Decoy20 didn't make it past Phase 1, another Meckler dud (anyone else remember Accordion Pill?). Seems to me that with the management changes, they plan to pivot to something else. Most likely a shift away from biotech, due to the lack of biotech/medical experience of the new investors. Low OS, only 2.24m shares. If the new investors can secure some funding when they announce their strategic pivot, ideally via a PIPE with multiple institutional investors, that could bring increased interest and volume here. Decent chance for a quick spike from these levels, if they can execute.
1 · Reply
TruthTooPower
TruthTooPower Mar. 31 at 7:54 PM
$INDP!!! Keep it Up!!! Just Before Open Telegraphing Where this is Headed!! !!!!!!!!!!!!!$2.75!!!!!!!!!!!!!!
0 · Reply
BadBankofGotham
BadBankofGotham Mar. 31 at 11:58 AM
0 · Reply
MikiTrader
MikiTrader Mar. 28 at 5:36 PM
$INDP After taking massive losses, it looks like they can’t play games anymore.😂
0 · Reply
TwongStocks
TwongStocks Mar. 25 at 2:15 AM
$INDP The new CEO and Chairman does not have a scientific or biotech background. Meckler and Dr. Pomerantz are out. Really looks like INDP is going to go through a complete transformation. Not sure what they'll end up doing, but I don't think this will be a biotech company anymore.
1 · Reply
TwongStocks
TwongStocks Mar. 24 at 8:42 PM
$INDP And here is the 8-k that identifies all the investors that bought Lazar's preferred shares: https://www.sec.gov/ix?doc=/Archives/edgar/data/1857044/000149315226012372/form8-k.htm Also, there will be massive changes at INDP. Meckler, Pomerantz, Maddaluna, & Hayes are resigning from the Board. Meckler is also resigning as co-CEO. Lazar resigns as co-CEO & Chairman, but remains on the Board. Junyi Dai is now Chairman & CEO.
1 · Reply
TwongStocks
TwongStocks Mar. 24 at 8:19 PM
$INDP New 13D filing from David Lazar. He sold most of his preferred shares. As a result, his beneficial ownership drops to 2,064,000 shares, 47.93%. He also resigned as co-CEO, but he retains his seat on the Board of Directors. https://www.sec.gov/Archives/edgar/data/1857044/000182912626002642/xslSCHEDULE_13D_X02/primary_doc.xml Under Item 6 at the bottom of the filing: He sold to Yun Yao (lead investor) and other purchasers: • 700,000 shares of Series AAA Preferred Stock (convertible to 105m shares) • 196,800 shares of Series AA Preferred Stock (convertible into 3.936m shares) • Lazar retains 103,200 shares of Series AA Preferred Stock (convertible into 2.064m shares). • Total sale price $11.2M. Lazar originally purchased all his preferred shares in Dec for $6M. So he got $11.2M and still kept 103.2k Series AA preferred shares. Pretty good swing for him. I guess his work here is done, he is no longer co-CEO. Picked up preferred shares, flipped them, and split.
0 · Reply
TruthTooPower
TruthTooPower Mar. 23 at 1:07 PM
$GRI!!! $INDP !!! $IRD !!! Get Ready To Rumble!!!
0 · Reply
TruthTooPower
TruthTooPower Mar. 20 at 12:04 PM
$INDP!!! 🤓
0 · Reply
TruthTooPower
TruthTooPower Mar. 20 at 11:56 AM
$INDP!!! This Traded At $2.74 at 4 am this Morning!!!
0 · Reply
TwongStocks
TwongStocks Mar. 17 at 8:49 PM
$INDP 10-K filed https://www.sec.gov/ix?doc=/Archives/edgar/data/1857044/000149315226010585/form10-k.htm Some notes: Looks like Decoy20 combo trial is done. "As of the date of this Annual Report on Form 10-K, we have discontinued further enrollment in the Combination Study and there are no participants remaining in the study. We do not have any current plans to initiate a new clinical trial." They plan to pursue a strategic transaction. They only report $8.5M as of Dec 31, so I assume they will be looking at another reverse merger. Hwoever, they only expect cash to fund operations into Q2 of 2026.
1 · Reply
TruthTooPower
TruthTooPower Mar. 17 at 5:04 PM
$INDP!!! A Earnings Beat by a Good Margin!!! We Will Break Out To New Recent Highs!!!
1 · Reply
AverageAndy
AverageAndy Mar. 16 at 6:36 PM
$INDP It’s been 6 plus years already!!!
0 · Reply
AutoAZTrader
AutoAZTrader Mar. 16 at 4:43 PM
$INDP Why is this even in the market? Total scam.
0 · Reply
Biomechanika
Biomechanika Mar. 12 at 12:39 PM
$INDP Yeah, its beating us.
1 · Reply
TruthTooPower
TruthTooPower Mar. 10 at 2:21 PM
$INDP!!! !!!!!!!!!!!BEAT!!!!!!!!!!!
0 · Reply
TruthTooPower
TruthTooPower Mar. 9 at 3:20 PM
$INDP!!! When They Beat, We Will Be Loaded With Praise and A 20% Gain!!! All Incoming!!!!!!!!!!
0 · Reply
MikiTrader
MikiTrader Mar. 7 at 5:02 AM
$INDP Curious why? You do not need to know.
0 · Reply
TruthTooPower
TruthTooPower Mar. 2 at 11:48 PM
$INDP!!! Take A Walk In The WILD SIDE!!!
0 · Reply
Godolphin1
Godolphin1 Mar. 2 at 11:03 PM
$INDP I have no idea re the bounce reverse splits have only worked once in my favour
0 · Reply
TruthTooPower
TruthTooPower Mar. 2 at 11:03 PM
$INDP!!! 🤓 they will be Chasing This Bad Boy!!!
0 · Reply
Godolphin1
Godolphin1 Mar. 2 at 11:02 PM
$INDP Hit 2.92 for a millisecond
0 · Reply